Ty 800

Drug Profile

Ty 800

Alternative Names: Ty800

Latest Information Update: 14 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celldex Therapeutics Inc
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Typhoid

Most Recent Events

  • 30 Sep 2008 AVANT Immunotherapeutics is now called Celldex Therapeutics
  • 03 Apr 2008 Immunogenicity, adverse event and pharmacodynamic data from a phase II trial in healthy volunteers released by AVANT Immunotherapeutics
  • 31 Jul 2007 Phase-II clinical trials in Typhoid in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top